Comments
Shasun Pharmaceuticals has entered into a licensing agreement with Switzerland- based Debiopharm for manufacturing and commercialisation of Huperzine-A, a drug used in the treatment of Alzheimer’s disease.
As per the agreement, Shasun Pharmaceuticals would be able to use Debiopharm technology for manufacturing synthetic Huperzine-A and commercialise it, Shasun Pharmaceuticals said in a filing to the BSE today.
“It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network,” Shasun Pharmaceuticals President Michel Spagnol said.
Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer’s disease.
Commenting on the development, Debiopharm Group President Mauvernay, said: “We are excited to have the opportunity to add value to this technology while contributing to improve people’s quality of life.”
Shares of Shasun Pharmaceuticals were trading at Rs 68.35 on the BSE in the afternoon trade, up 4.51 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.